The sharp rise comes after PulseNmore announced that its FDA-approved home ultrasound technology, cleared for use in the United States roughly five months ago, will be integrated into Ouma’s virtual care model for pregnancy monitoring across 50 U.S. states. The integration will be carried out through partnerships with insurers, healthcare systems, obstetrics groups, and community health centers.
Under the agreement, PulseNmore’s device will be used to allow clinical teams to maintain continuous remote contact with pregnant patients throughout their pregnancy, expanding the depth and frequency of fetal monitoring outside traditional clinical settings. For PulseNmore, the deal represents a key step in expanding its U.S. footprint through additional payer and healthcare system partnerships.
PulseNmore develops a handheld ultrasound device that allows pregnant women to perform scans at home, transmitting imaging data to clinicians for remote review. The company went public on the Tel Aviv Stock Exchange in 2021 at a valuation of around $200 million, during a wave of listings by “venture-style” healthcare and technology companies that later faced investor disappointment. Since its IPO, the company’s valuation declined to roughly $80 million, and about a year ago General Electric (GE) sold its stake in the company, a move the market interpreted as a lack of confidence. PulseNmore also listed on Nasdaq earlier this year.
In its 2025 financial report, PulseNmore recorded $12.5 million in revenue and a $5 million net loss. The company expects to move toward operational breakeven in the coming year.
Speaking to ynet, CEO Elazar Sonnenschein described the partnership as a major breakthrough for the company. He said that in the United States, each state requires separate regulatory approval for interpreting ultrasound results, and the agreement with Ouma provides access across all 50 states without the need for individual approvals. He added that pregnancy care is undergoing a structural shift toward patient-centered and virtual models, and that PulseNmore is effectively moving ultrasound diagnostics outside the clinic and embedding them into existing digital care pathways.
Sonnenschein also noted that about 35% of U.S. counties are classified as “maternity care deserts,” areas with limited or no access to obstetric services within a reasonable distance. He said the company’s home ultrasound system, integrated into remote care models, could play a significant role in supporting pregnant women in these underserved regions.
Dr. Sini Harari of Ouma said the company serves pregnant women who often face significant geographic and logistical barriers to care, including those living in underserved or low-resource communities. She said PulseNmore’s technology allows much of prenatal monitoring to be conducted at home while maintaining continuous clinical oversight, enabling doctors to review data and guide care remotely. According to her, this strengthens continuity of care within virtual pregnancy models, particularly for patients with limited access to specialist services.
In Israel, PulseNmore has a strategic partnership with Clalit Health Services, through which tens of thousands of home ultrasound devices are being distributed for pregnancy monitoring. The company’s chairman is Yoni Adar, former chairman of Mazor Robotics.